The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Guselkumab Studied to Treat RA, Plaque Psoriasis

Guselkumab Studied to Treat RA, Plaque Psoriasis

September 15, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Guselkumab Studied to Treat RA & Plaque Psoriasis

Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA).

You Might Also Like
  • Guselkumab Studied to Treat RA & Plaque Psoriasis
  • Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
  • Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA
Explore This Issue
September 2015
Also By This Author
  • Rheumatology Drug Updates, Trials, Safety Data

On June 11, 2015, at the 2015 meeting of the European League Against Rheumatism (EULAR) in Rome, Italy, researchers presented an evaluation of the safety and efficacy of treating patients with active RA (n=274) with guselkumab or ustekinumab, despite methotrexate (MTX) treatment. This randomized, multicenter, double-blind, placebo-controlled, parallel-group study involved patients with six or more tender joints (TJC) and six swollen joints (SJC) with a CRP of at least 0.80 mg/dL.2 Randomized patients received placebo; ustekinumab (UST) 90 mg on Weeks 0, 4 and then every eight weeks; UST 90 mg on Weeks 0, 4 and then every 12 weeks; GUS 200 mg on Weeks 0, 4 and then every eight weeks; or GUS 50 mg on Weeks 0, 4 and then every eight weeks. MTX doses ranged from 10–25 mg weekly and had to be stable for a minimum of 12 weeks prior to randomization. Prednisone 10 mg daily or less, and non-steroidal anti-inflammatory agents were permitted.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Placebo-treated patients at Week 12 were given UST 90 mg on Weeks 16, 20 and 28 if they did not have at least a 10% improvement in both TJC and SJC. The number of patients obtaining an ACR20 was not significantly different between the groups.

Some differences were noted in secondary endpoints. More than one treatment-emergent adverse event (TEAE) occurred at Week 48 for 46% of placebo-treated patients, 50% of combined UST-treated patients and 43% of combined GUS-treated patients. There were also two cases of malignancy, squamous cell lung cancer in one UST 90 mg every 12-weeks-treated patient, and breast cancer in one GUS 200 mg every eight-weeks-treated patient. ACR20 efficacy at Week 28 was not seen in GUS- or UST-treated patients with active RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Minor improvements were seen in some secondary endpoints. These results show that IL-12 and/or IL-23 inhibition lack sign and symptom alleviation in patients with active RA. GUS is currently in Phase 3 clinical trials for the treatment of moderate to severe plaque psoriasis in both the U.S. and European Union.

Biosimilar Drug Updates

In one Phase 3 study presented at the 2015 meeting of the European League Against Rheumatism (EULAR), researchers randomized 596 patients to receive either etanercept (ETN) or an etanercept biosimilar (SB4) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) therapy.3 Patients received SB4 50 mg (n=299) or ETN 50 mg (n=297) administered subcutaneously weekly for 52 weeks. Demographics were similar between the two treatment groups.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: biosimilar, clinical trial, Drugs, guselkumab, outcome, plaque psoriasis, Rheumatoid arthritis, rheumatology, SafetyIssue: September 2015

You Might Also Like:
  • Guselkumab Studied to Treat RA & Plaque Psoriasis
  • Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
  • Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA
  • Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.